Kristi Rosa


Sintilimab Plus Chemotherapy Induces Superior Survival in EGFR-Mutated Nonsquamous NSCLC

October 19, 2021

Sintilimab, a bevacizumab biosimilar injection, met the primary end point of the phase 3 ORIENT-31 trial by significantly increasing progression-free survival in patients with EGFR-mutated, nonsquamous, non–small cell lung cancer.

Axitinib/Pembrolizumab Combination Improves Survival in Metastatic RCC, But Only Marginally

October 17, 2021

A real-world survival analysis showed that patients with metastatic RCC treated with axitinib plus pembrolizumab did not experience significantly improved survival outcomes compared with patients treated with ipilimumab plus nivolumab.